financetom
Business
financetom
/
Business
/
D.R. Horton Unusual Options Activity For August 21
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
D.R. Horton Unusual Options Activity For August 21
Aug 22, 2024 12:56 AM

High-rolling investors have positioned themselves bullish on D.R. Horton ( DHI ) , and it's important for retail traders to take note.

This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DHI often signals that someone has privileged information.

Today, Benzinga's options scanner spotted 17 options trades for D.R. Horton ( DHI ). This is not a typical pattern.

The sentiment among these major traders is split, with 52% bullish and 35% bearish. Among all the options we identified, there was one put, amounting to $47,600, and 16 calls, totaling $1,056,708.

Expected Price Movements

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $135.0 and $190.0 for D.R. Horton ( DHI ), spanning the last three months.

Volume & Open Interest Development

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for D.R. Horton's ( DHI ) options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of D.R. Horton's ( DHI ) whale activity within a strike price range from $135.0 to $190.0 in the last 30 days.

D.R. Horton Option Activity Analysis: Last 30 Days

Noteworthy Options Activity:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
DHI CALL SWEEP BULLISH 08/23/24 $6.6 $6.5 $6.6 $180.00 $310.2K 780 542
DHI CALL SWEEP BULLISH 08/30/24 $4.0 $3.7 $3.9 $185.00 $116.5K 282 1.7K
DHI CALL SWEEP BULLISH 08/30/24 $3.7 $3.4 $3.51 $185.00 $109.2K 282 1.2K
DHI CALL SWEEP BEARISH 08/30/24 $3.4 $3.2 $3.4 $185.00 $76.7K 282 424
DHI CALL SWEEP BULLISH 09/20/24 $4.0 $3.7 $4.0 $190.00 $60.0K 1.5K 156

About D.R. Horton

D.R. Horton ( DHI ) is a leading homebuilder in the United States with operations in 118 markets across 33 states. D.R. Horton ( DHI ) mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's ( DHI ) headquarters are in Arlington, Texas, and it manages six regional segments across the United States.

After a thorough review of the options trading surrounding D.R. Horton ( DHI ), we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Current Position of D.R. Horton

With a trading volume of 1,187,179, the price of DHI is up by 3.38%, reaching $185.68.

Current RSI values indicate that the stock is may be approaching overbought.

Next earnings report is scheduled for 76 days from now.

Expert Opinions on D.R. Horton

2 market experts have recently issued ratings for this stock, with a consensus target price of $194.0.

Maintaining their stance, an analyst from Keefe, Bruyette & Woods continues to hold a Outperform rating for D.R. Horton ( DHI ), targeting a price of $208.

An analyst from JP Morgan persists with their Neutral rating on D.R. Horton ( DHI ), maintaining a target price of $180.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for D.R. Horton ( DHI ), Benzinga Pro gives you real-time options trades alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Treatment
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Treatment
Jun 18, 2025
08:12 AM EDT, 06/18/2025 (MT Newswires) -- Biogen (BIIB) said Wednesday it has begun dosing participants in a phase 3 trial to assess omaveloxolone for treating Friedreich ataxia, a rare neurodegenerative disorder, in children aged between 2 and 16 years. The study will assess the efficacy and safety of omaveloxolone in both ambulatory and non-ambulatory children, with participants randomized to...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Array Technologies Boosts Solar Play With $179 Million APA Acquisition
Array Technologies Boosts Solar Play With $179 Million APA Acquisition
Jun 18, 2025
Array Technologies Inc. ( ARRY ) on Wednesday said it is set to enhance its solar technology offerings through a definitive agreement to acquire APA Solar LLC, a U.S.-based provider of engineered solar foundation systems and fixed-tilt mounting solutions. The acquisition is valued at approximately $179 million and is projected to close in the third quarter of 2025, pending customary...
Biomea Says Preclinical Results Show 'Robust' Weight Loss From Investigational Drug
Biomea Says Preclinical Results Show 'Robust' Weight Loss From Investigational Drug
Jun 18, 2025
08:12 AM EDT, 06/18/2025 (MT Newswires) -- Biomea Fusion ( BMEA ) said Wednesday that preclinical data for its investigational weight loss drug, BMF-650, showed robust weight loss and appetite suppression. The study, conducted with monkeys, showed 12% to 15% body weight reductions over 28 days, the company said. BMF-650 was well-tolerated, the company said, adding that plans to file...
Copyright 2023-2026 - www.financetom.com All Rights Reserved